Key features and details
- Rabbit polyclonal to Vaccinia Virus
- Suitable for: ELISA, IHC-Fr
- Reacts with: Vaccinia virus
- Isotype: IgG
Product nameAnti-Vaccinia Virus antibody
See all Vaccinia Virus primary antibodies
DescriptionRabbit polyclonal to Vaccinia Virus
SpecificityThis antibody reacts with purified Virions. It does not react with uninfected cells.
Tested applicationsSuitable for: ELISA, IHC-Frmore details
Species reactivityReacts with: Vaccinia virus
Native virus, Lister strain.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage bufferpH: 7.40
Preservative: 0.1% Sodium azide
Concentration information loading...
Purification notesThis antibody is greater than 95% pure.
Our Abpromise guarantee covers the use of ab35219 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ELISA||1/500 - 1/2000.|
|IHC-Fr||Use at an assay dependent concentration.|
RelevanceVaccinia virus is an Orthopoxvirus, containing double stranded DNA. Fusion protein plays an important role in the entry of enveloped virus into cells. As vaccinia virus has a wide host range, it is conceivable that certain cellular components that are ubiquitously expressed on the cell mediate virus infection. The study of the entry process, attachment, fusion and the proteins and receptors involved is complex. During vaccinia virus infection, the fusion process is attributed to the action of the 14KDa protein (A27L). The N terminus of this protein recognises heparan sulfate on the cell surface. It interacts with the negative charges of sulfates of glycosaminoglycans (GAGs). Therefore, antibodies that recognize this 14KDa protein are able to neutralize vaccinia virus infection and enable identification other viral and cellular proteins which participate in the vaccinia virus entry process.
- A27L antibody
- Orthopoxvirus antibody
ab35219 has been referenced in 19 publications.
- Islam SMBU et al. Engineering and Characterization of Oncolytic Vaccinia Virus Expressing Truncated Herpes Simplex Virus Thymidine Kinase. Cancers (Basel) 12:N/A (2020). PubMed: 31963415
- Warner SG et al. A Novel Chimeric Poxvirus Encoding hNIS Is Tumor-Tropic, Imageable, and Synergistic with Radioiodine to Sustain Colon Cancer Regression. Mol Ther Oncolytics 13:82-92 (2019). PubMed: 31061881
- Schuelke MR et al. Diverse immunotherapies can effectively treat syngeneic brainstem tumors in the absence of overt toxicity. J Immunother Cancer 7:188 (2019). PubMed: 31315671
- Ylösmäki L et al. Harnessing therapeutic viruses as a delivery vehicle for RNA-based therapy. PLoS One 14:e0224072 (2019). PubMed: 31644552
- O'Leary MP et al. Novel oncolytic chimeric orthopoxvirus causes regression of pancreatic cancer xenografts and exhibits abscopal effect at a single low dose. J Transl Med 16:110 (2018). PubMed: 29699566